Friday, January 06, 2023 12:53:59 PM
underpar71,
Just a reminder that Linda Powers is more beholden to what regulators want right now than what investors want right now. NWBO got a reprimand for promoting years ago and so they will not do anything that looks like promotion at all right now. Someone reported that even Specials revenue is not being listed as such because that is too touchy for them to do because regulators don’t want them even hinting at this. You MUST remember that the screening hold was essentially a regulator green light IF and as long as NWBO did not mess up along the way to achieving commercial scale manufacturing and properly submitted BLA/MAA while keeping the pressure off of regulators. NWBO is hog tying themselves because of regulator support which gives regulators the positive attention while NWBO takes the heat so that regulator moves, deliberately slow, are not viewed as favoritism. This is “the process” that satisfies the influence of big pharma profits and keeps NWBO silenced all while patients are sacrificed on the altar of “the process”. Clinicians like Dr. Ashkan and Dr. Linda Liau have expressed their frustrations but also realize what is going on and have been less openly vocal about the slowness of this more recently. They see the consequences of all of this on a daily basis up close and personal. Must be really tough for them to deal with knowing that a life saving treatment is in view but just out of reach for their patients. Glad I am just an investor. Best wishes.
Just a reminder that Linda Powers is more beholden to what regulators want right now than what investors want right now. NWBO got a reprimand for promoting years ago and so they will not do anything that looks like promotion at all right now. Someone reported that even Specials revenue is not being listed as such because that is too touchy for them to do because regulators don’t want them even hinting at this. You MUST remember that the screening hold was essentially a regulator green light IF and as long as NWBO did not mess up along the way to achieving commercial scale manufacturing and properly submitted BLA/MAA while keeping the pressure off of regulators. NWBO is hog tying themselves because of regulator support which gives regulators the positive attention while NWBO takes the heat so that regulator moves, deliberately slow, are not viewed as favoritism. This is “the process” that satisfies the influence of big pharma profits and keeps NWBO silenced all while patients are sacrificed on the altar of “the process”. Clinicians like Dr. Ashkan and Dr. Linda Liau have expressed their frustrations but also realize what is going on and have been less openly vocal about the slowness of this more recently. They see the consequences of all of this on a daily basis up close and personal. Must be really tough for them to deal with knowing that a life saving treatment is in view but just out of reach for their patients. Glad I am just an investor. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
